Defiance Next Gen Altered Experience ETF (PSY)
Defiance Next Gen Altered Experience ETF operates in the Asset Management industry of the Financial Services sector, headquartered in DE, US. The stock last traded at $5.90, down 0.51% on the session, giving a market capitalisation of $4.7M. Its beta of 0.00 implies it has historically moved less than the broad market.
This fund is designed to mirror a systematically constructed index. This index evaluates the performance of companies engaged in specific, legally authorized activities, always in adherence to national laws. These activities encompass the fields of medical psychedelics, therapeutic cannabis, cannabis-derived pharmaceuticals, cannabidiol (CBD) derivatives, and ketamine. To achieve its financial goals, the fund utilizes a full replication approach, meaning it directly invests in all the constituent securities of the underlying index, striving to maintain their proportional weightings. It functions as a non-diversified investment product.
Defiance Next Gen Altered Experience ETF is most often compared with the following Financial Services names: